The Funding Dilemma

#Energy Bio-innovators and entrepreneurs are often frustrated that investors don?t see the scope of biological opportunity. The industry?s funding models remain in flux. With appetite for risk unpredictable and a landscape that?s often unexplored, what?s a startup to do? How are big companies responding? In this video from our June 17 Techonomy Bio conference, Paul Gurney of McKinsey & Company moderates a discussion with Beth Seidenberg of Kleiner Perkins Caufield & Byers, Lindy Fishburne of Breakout Labs and the Thiel Foundation, and Steve Jurvetson of Draper Fisher Jurvetson and Synthetic Genomics, Inc.http://ift.tt/UQ5jUy http://bit.ly/15KdByZ